"rationale","label","name","uuid:ID","id","instanceType","description"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","Study Design 1","88f98149-d4d2-435a-b641-6035c7193841","StudyDesign_1","StudyDesign","The main design for the study"
